BDBM50158869 CHEMBL3786182::US10836743, Compound GSK-2879552::US11254676, Example Control::US11873292, Compound GSK2879552

SMILES OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1

InChI Key InChIKey=LRULVYSBRWUVGR-FCHUYYIVSA-N

Data  3 KI  23 IC50  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 50158869   

TargetLysine-specific histone demethylase 1A(Homo sapiens (Human))
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50158869(CHEMBL3786182 | US10836743, Compound GSK-2879552 |...)
Affinity DataIC50:  404nMAssay Description:Principle: LSD1 specifically removes the methylation modification at K4 lysine on H3 polypeptide substrate, making it a substrate without methylation...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAmine oxidase [flavin-containing] A(Homo sapiens (Human))
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50158869(CHEMBL3786182 | US10836743, Compound GSK-2879552 |...)
Affinity DataIC50: >1.00E+5nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetAmine oxidase [flavin-containing] B(Homo sapiens (Human))
Shanghai Institute of Materia Medica

US Patent
LigandPNGBDBM50158869(CHEMBL3786182 | US10836743, Compound GSK-2879552 |...)
Affinity DataIC50: >1.00E+5nMAssay Description:Principle: A specific luciferin derivative was used as a substrate. MAOA or MAOB can catalyze the conversion of substrate to luciferin methyl ester. ...More data for this Ligand-Target Pair
In DepthDetails US Patent